Investment Thesis
Reviva is a pre-revenue/minimal-revenue stage pharmaceutical company with unsustainable cash burn of $3.8M per quarter against only $122.9K in revenue, resulting in -2601% net margins. Despite a strong absolute cash position of $22.2M and zero debt, the company is consuming capital rapidly and has approximately 1.5 years of runway at current burn rates. Positive 81.5% YoY revenue growth is meaningless from near-zero baseline and does not demonstrate clear commercialization or product-market viability.
Strengths
- Strong cash position of $22.2M with no debt provides operational flexibility and eliminates refinancing risk in near term
- Excellent liquidity ratios (3.85x current/quick) indicate no immediate solvency concerns
- Revenue growing 81.5% YoY suggests early product traction or market entry, though from negligible base
Risks
- Unsustainable cash burn of $3.8M per period against minimal revenue creates 18-month funding runway at current rates
- Extreme operating losses (-2663% margin) with no visible path to profitability indicate fundamental business model challenges or pre-commercialization stage with execution risk
- Minimal revenue generation ($122.9K) reveals severe commercialization failures, product rejection, or lack of market demand; survival depends entirely on securing additional capital or dramatic revenue acceleration
Key Metrics to Watch
- Quarterly operating cash burn rate and remaining cash runway duration
- Revenue growth trajectory and gross margin achievement once revenue scales meaningfully
- Pipeline progress and FDA approval status of candidate drugs to assess probability of future revenue sustainability
Financial Metrics
Revenue
122.9K
Net Income
-3.2M
EPS (Diluted)
$0.00
Free Cash Flow
-3.8M
Total Assets
23.6M
Cash
22.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-2,663.0%
Net Margin
-2,601.2%
ROE
-18.3%
ROA
-13.6%
FCF Margin
-3,093.8%
Balance Sheet & Liquidity
Current Ratio
3.85x
Quick Ratio
3.85x
Debt/Equity
0.00x
Debt/Assets
26.0%
Interest Coverage
-938.33x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T09:15:11.070747 |
Data as of: 2026-03-31 |
Powered by Claude AI